IL1B and breast cancer: As reported in cohort one, 4T1 mammary tumors resulted in a significant reduction in body mass (Fig. 6A, F2,41 = 3.377, p < 0.05), increase in spleen mass (Fig. 6C, H = 31.48, p < 0.001), and increases in hippocampal cytokine concentrations of IL-1β (Fig. 6D, H = 24.59, p < 0.0001) compared to the non-tumor bearing vehicle-treated controls.